期刊
CURRENT MEDICAL RESEARCH AND OPINION
卷 26, 期 8, 页码 1793-1797出版社
TAYLOR & FRANCIS LTD
DOI: 10.1185/03007995.2010.489341
关键词
ACCORD trial; Dyslipidaemia; High-density lipoprotein cholesterol; Residual cardiovascular risk; Triglycerides; Type 2 diabetes
资金
- ISIS
- Abbott
- AstraZeneca
- Bayer
- E. Lilly
- Solvay Pharma
- GSK
- LifeScan
- Menarini
- MSD
- Novartis
- NovoNordisk
- Nycomed
- Pfizer
- Sanofi-Aventis
- Servier
Most type 2 diabetes patients remain at high residual risk of cardiovascular events despite best treatment. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial aimed to address this challenge, by evaluating whether intensive control of glycaemia and high blood pressure, or as in ACCORD Lipid, extending lipid treatment with the combination of fenofibrate plus simvastatin, could impact this risk. ACCORD Lipid showed that treatment beyond low-density lipoprotein cholesterol was not appropriate for most type 2 diabetes patients. However, a subgroup analysis did suggest additional benefit in patients with atherogenic dyslipidaemia, the combination of high baseline triglycerides (>= 204 mg/dL or 2.3 mmol/L) and low baseline plasma levels of high-density lipoprotein cholesterol (<= 34 mg/dL or 0.88 mmol/L). This finding is concordant with subgroup analyses from other fibrate trials in patients with high triglycerides and low plasma levels of high-density lipoprotein cholesterol, and consistent with current guideline recommendations. This commentary from the Residual Risk Reduction Initiative (R(3)i), discusses the ACCORD Lipid study results and the next steps to establish the clinical relevance of these findings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据